This article relies largely or entirely on a single source. (November 2014)
CEPP is an acronym for the name of a chemotherapy regimen that is intended for treatment of aggressive Non-Hodgkin Lymphomas. Unlike CHOP, this chemotherapy regimen does not contain doxorubicin or any other anthracycline. Thus, it can be used in patients with severe cardiovascular diseases and contraindications for doxorubicin-containing regimens. There are 2 modifications of CEPP - with the addition of bleomycin, called CEPP (B), and without bleomycin - ordinary CEPP.
[R]-CEPP(B) regimen consists of:
- (R)ituximab - a monoclonal antibody that is able to kill CD20-positive B cells, either normal or malignant;
- (C)yclophosphamide - an alkylating antineoplastic agent;
- (E)toposide - a topoisomerase inhibitor from the epipodophyllotoxin group;
- (P)rocarbazine - an alkylating antineoplastic agent;
- (P)rednisone or (P)rednisolone - a glucocorticoid hormone that has the ability to cause apoptosis and lysis of lymphocytes, either normal or malignant;
- (B)leomycin - an antitumor antibiotic.
|(R)ituximab||375 mg/m2||IV infusion||Day 1|
|(C)yclophosphamide||600 mg/m2||IV infusion||Days 1 and 8|
|(E)toposide||70 mg/m2||IV infusion||Days 1-3|
|(P)rocarbazine||60 mg/m2||PO qd||Days 1-10|
|(P)rednisone or (P)rednisolone||60 mg/m2||PO qd||Days 1-10|
|(B)leomycin||10 IU/m2||IV bolus||Day 1|